The outcomes from a recent drug trial in the UK demonstrate that the breathing normalization method developed by a Russian physiologist K. Buteyko MD-PhD 60 years ago defeats COVID.
According to scientists at Oxford University, one new approach is showing remarkable results. The trial enrolled over 11,500 COVID-19 patients from 175 hospitals and offered a variety of drug treatments – only one showed a significant life-saving effect.
The drug that surprised everyone? A low-dose corticosteroid, prescribed commonly as medicine for respiratory illness, proved highly effective. Dexamethasone is an inexpensive and easy to manufacture drug that reduced deaths for patients on ventilators by one-third, and for patients receiving oxygen therapy by one-fifth. Peter Horby, one of the Chief Investigators for of the RECOVERY Trial, said, ‘Dexamethasone is the first drug to be shown to improve survival in COVID-19.
In April, the Breathing Center published an article where the use of low-dose steroid medication was recommended as the only drug defense against COVID-19. The author of the article, A. Novozhilov MD, stated that this approach works because corticosteroids calm the immune response and inflammation in patients who develop respiratory complications, especially as the result of the virus. He explained why a common and low-cost drug like Dexamethasone that suppresses the immune system and prevents the release of substances in the body that cause inflammation should be used as a COVID-19 treatment.
